Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
People diagnosed with invasive breast cancer and the following:
Patients are excluded if they:
This study is open in multiple sites in Colorado, Connecticut, Washington, DC, Maryland, Massachusetts, New Jersey, North Carolina, Rhode Island, and Texas.
INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug Cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited mutation in BRCA1 or BRCA2.
This is a neoadjuvant study which means that patients will receive the chemotherapy before having surgery to remove the remaining tumor. Only patients who have not had their breast cancer tumor removed yet will be eligible for this study.
This is a randomized, open-label, 2-arm treatment study.
Principal Investigator: Nadine Tung, MD
Contact information: Phone: (617)667-7081 email@example.com